UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

FLI-1-driven regulation of endothelial cells in human diseases

Journal of translational medicine, 2024-08, Vol.22 (1), p.740-14, Article 740

2024

Volltextzugriff (PDF)

Association of Life’s Essential 8 with metabolic dysfunction-associated steatotic liver disease (MASLD), a cross-sectional study from the NHANES 2003–2018

Scientific reports, 2024-07, Vol.14 (1), p.17188-10, Article 17188

2024

Volltextzugriff (PDF)

Association of volatile organic compound levels with chronic obstructive pulmonary diseases in NHANES 2013–2016

Scientific reports, 2024-07, Vol.14 (1), p.16085-11, Article 16085

2024

Volltextzugriff (PDF)

ADAR1 Promotes Invasion and Migration and Inhibits Ferroptosis via the FAK/AKT Pathway in Colorectal Cancer

Molecular carcinogenesis, 2024-09

2024

Volltextzugriff (PDF)

A multicenter real-world study on the efficacy and safety of anlotinib-based treatment for metastatic breast cancer

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.e13120-e13120

2024

Volltextzugriff (PDF)

Reply to Comment on "Association Between Cardiovascular Health and Retinopathy in US Adults: From NHANES 2005-2008

American journal of ophthalmology, 2024-09, Vol.265, p.305-306

2024

Volltextzugriff (PDF)

CircARAP2 controls sMICA-induced NK cell desensitization by erasing CTCF/PRC2-induced suppression in early endosome marker RAB5A

Cellular and molecular life sciences : CMLS, 2024-12, Vol.81 (1), p.307, Article 307

2024

Volltextzugriff (PDF)

A phase Ib/IIa trial to evaluate the safety and efficacy of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced NSCLC

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.8533-8533

2024

Volltextzugriff (PDF)

First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients with advanced melanoma: Safety and efficacy results from a phase I study

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.9562-9562

2024

Volltextzugriff (PDF)

A phase 1 study of HRS-1167 (M9466), a highly selective PARP1 inhibitor, in patients (pts) with advanced solid tumors

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.3154-3154

2024

Volltextzugriff (PDF)

A phase Ib study of PI3Kα inhibitor risovalisib mesylate in combination with fulvestrant in patients with PIK3CA -mutated, HR+/HER2- advanced breast cancer

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.1047-1047

2024

Volltextzugriff (PDF)

Maintenance therapy with anlotinib after induction therapy with platinum-based chemotherapy for advanced non-small-cell lung cancer: A pooled analysis of 2 single-arm trials

Medicine (Baltimore), 2024-07, Vol.103 (27), p.e38459

2024

Volltextzugriff (PDF)

First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients with advanced colorectal cancer: Safety and efficacy results from a phase I study

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.3593-3593

2024

Volltextzugriff (PDF)

Amivantamab plus lazertinib in atypical EGFR -mutated advanced non-small cell lung cancer (NSCLC): Results from CHRYSALIS-2

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.8516-8516

2024

Volltextzugriff (PDF)

Circulating tumor DNA-based stratification strategy for chemotherapy plus PD-1 inhibitor in advanced non-small-cell lung cancer

Cancer cell, 2024-09, Vol.42 (9), p.1598-1613.e4

2024

Volltextzugriff (PDF)

Befotertinib for patients with pretreated EGFR T790M mutated locally advanced or metastatic NSCLC: Final overall survival results from a phase 2 trial

Lung cancer (Amsterdam, Netherlands), 2024-09, Vol.195, p.107901, Article 107901

2024

Volltextzugriff (PDF)

Foritinib in advanced ROS1-rearranged non-small-cell lung cancer in China: a multicentre, open-label, single-arm, phase 2 study

The lancet respiratory medicine, 2024-09, Vol.12 (9), p.671-680

2024

Volltextzugriff (PDF)

Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial

The lancet respiratory medicine, 2024-08, Vol.12 (8), p.589-598

2024

Volltextzugriff (PDF)

Patient-reported outcomes for the phase 3 FURLONG study of furmonertinib versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancerResearch in context

The Lancet regional health. Western Pacific, 2024-07, Vol.48, p.101122

2024

Volltextzugriff (PDF)

Patient-reported outcomes for the phase 3 FURLONG study of furmonertinib versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer

The Lancet regional health. Western Pacific, 2024-07, Vol.48, p.101122, Article 101122

2024

Volltextzugriff (PDF)

Abstract CT235: RNA-seq molecular subtypes and gene expression signatures in the phase 3 IMpower151 study of 1L bevacizumab + pemetrexed/paclitaxel ± atezolizumab in metastatic NSCLC

Cancer research (Chicago, Ill.), 2024-04, Vol.84 (7_Supplement), p.CT235-CT235

2024

Volltextzugriff (PDF)

Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR ‐mutated, advanced non‐small cell lung cancer: data from a randomized phase III trial (AENEAS)

Cancer communications (London, England), 2024-07

2024

Volltextzugriff (PDF)

Abstract CT246: Open-label, single-arm, multicenter, phase 2 trial of garsorasib in KRAS G12C-mutated non-small-cell lung cancer

Cancer research (Chicago, Ill.), 2024-04, Vol.84 (7_Supplement), p.CT246-CT246

2024

Volltextzugriff (PDF)

1 – 24 von 24

Suche als RSS-Feed

Aktive Filter

SpracheChinesisch

Nur zeigenMit Volltextzugriff

Neu hinzugefügt... seit 90 Tagen

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(24)

Publikationsform

Artikel
(24)

Sprache

Englisch
(24)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

FLI-1-driven regulation of endothelial cells in human diseases

Association of Life’s Essential 8 with metabolic dysfunction-associated steatotic liver disease (MASLD), a cross-sectional study from the NHANES 2003–2018

Association of volatile organic compound levels with chronic obstructive pulmonary diseases in NHANES 2013–2016

ADAR1 Promotes Invasion and Migration and Inhibits Ferroptosis via the FAK/AKT Pathway in Colorectal Cancer

A multicenter real-world study on the efficacy and safety of anlotinib-based treatment for metastatic breast cancer

Reply to Comment on "Association Between Cardiovascular Health and Retinopathy in US Adults: From NHANES 2005-2008

CircARAP2 controls sMICA-induced NK cell desensitization by erasing CTCF/PRC2-induced suppression in early endosome marker RAB5A

A phase Ib/IIa trial to evaluate the safety and efficacy of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced NSCLC

First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients with advanced melanoma: Safety and efficacy results from a phase I study

A phase 1 study of HRS-1167 (M9466), a highly selective PARP1 inhibitor, in patients (pts) with advanced solid tumors

A phase Ib study of PI3Kα inhibitor risovalisib mesylate in combination with fulvestrant in patients with PIK3CA -mutated, HR+/HER2- advanced breast cancer

Maintenance therapy with anlotinib after induction therapy with platinum-based chemotherapy for advanced non-small-cell lung cancer: A pooled analysis of 2 single-arm trials

First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients with advanced colorectal cancer: Safety and efficacy results from a phase I study

Amivantamab plus lazertinib in atypical EGFR -mutated advanced non-small cell lung cancer (NSCLC): Results from CHRYSALIS-2

Finotonlimab with chemotherapy in recurrent or metastatic head and neck cancer: a randomized phase 3 trial

Circulating tumor DNA-based stratification strategy for chemotherapy plus PD-1 inhibitor in advanced non-small-cell lung cancer

Befotertinib for patients with pretreated EGFR T790M mutated locally advanced or metastatic NSCLC: Final overall survival results from a phase 2 trial

Foritinib in advanced ROS1-rearranged non-small-cell lung cancer in China: a multicentre, open-label, single-arm, phase 2 study

Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial

Patient-reported outcomes for the phase 3 FURLONG study of furmonertinib versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancerResearch in context

Patient-reported outcomes for the phase 3 FURLONG study of furmonertinib versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer

Abstract CT235: RNA-seq molecular subtypes and gene expression signatures in the phase 3 IMpower151 study of 1L bevacizumab + pemetrexed/paclitaxel ± atezolizumab in metastatic NSCLC

Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR ‐mutated, advanced non‐small cell lung cancer: data from a randomized phase III trial (AENEAS)

Abstract CT246: Open-label, single-arm, multicenter, phase 2 trial of garsorasib in KRAS G12C-mutated non-small-cell lung cancer

Aktive Filter

Suchergebnisse filtern